William Aronson

· Professor of Urology, Chief of Urology at Olive View UCLA Medical Center and Chief of Urologic Oncology, Veterans Administration West Los Angeles.

University of California, Los Angeles · Urology

Active 1936–2026

h-index87

Citations28.5k

Papers765107 last 5y

Funding$79.9M

Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.

Faculty page

See your match with William Aronson — sign in to PhdFit.Sign in

About

William Aronson is a Professor-in-Residence in the Department of Urology at UCLA's David Geffen School of Medicine. His research activities and funding focus on the role of GPR120 and macrophages in dietary omega-3 fatty acid inhibition of prostate cancer. He has contributed to numerous studies related to prostate cancer, including the quantification of the impact of biochemical recurrence after radical prostatectomy on overall mortality, and the effects of omega-3 fatty acid treatment on prostate cancer progression. His work also encompasses the development of clinical-genomic risk systems for prognostication in patients with localized prostate cancer, as well as the influence of diet and lifestyle on prostate cancer outcomes. Aronson's research extends to evaluating racial disparities in prostate cancer pathology prediction models, the risk of progression after early androgen deprivation therapy, and the safety and efficacy of various treatments in diverse populations. His contributions are characterized by a focus on improving understanding of prostate cancer biology, risk assessment, and therapeutic strategies.

Research topics

Internal medicine
Medicine
Urology
Oncology
Chemistry
Food science
Biochemistry
Pharmacology

Selected publications

Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)
European Urology · 2020 · 179 citations
DOI
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
Circulation · 2021 · 143 citations
BACKGROUND: The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men with prostate cancer and known atherosclerotic cardiovascular disease remains controversial. METHODS: In this international, multicenter, prospective, randomized, open-label trial, men with prostate cancer and concomitant atherosclerotic cardiovascular disease were randomly assigned 1:1 to receive the GnRH antagonist degarelix or the GnRH agonist leuprolide for 1…
Publisher OA PDF DOI
Prospective randomized trial evaluating blood and prostate tissue concentrations of green tea polyphenols and quercetin in men with prostate cancer
Food & Function · 2020 · 46 citations
Senior authorCorresponding
We evaluated if chronic consumption of quercetin (Q) with green tea extract (GTE) enhances the bioavailability of GT polyphenols (GTPs) and reduces methylation activity as previously observed in mouse xenograft tumors. In this prospective, randomized, parallel design, placebo controlled study, thirty-one men with prostate cancer consumed daily 1 gram of GTE (830 mg of GTP) with 800 mg of Q (GT + Q) or placebo (GT + PL) for four weeks before prostatectomy. First morning voided urine was collected…
Publisher OA PDF DOI
Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study
European Urology · 2020 · 28 citations
DOI
High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial
Journal of Clinical Oncology · 2024-12-13 · 25 citations
articleOpen access1st authorCorresponding
PURPOSE Men on active surveillance (AS) for prostate cancer are extremely interested in dietary changes or supplements to prevent progression of their disease. We sought to determine whether a high omega-3, low omega-6 fatty acid diet with fish oil capsules (D + FO) decreases proliferation (Ki-67) in prostate biopsies in men with prostate cancer on AS over a 1-year time period. METHODS In this phase II, prospective randomized trial, men (N = 100) with grade group 1 or 2 prostate cancer who elect…
Publisher OA PDF DOI

Recent grants

Career Enhancement Program
NIH · $35.9M · 2002–2025
Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
NIH · $1.7M · 2018–2023
Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
NIH · $445k · 2018–2023

Frequent coauthors

Stephen J. Freedland
Durham VA Medical Center
1015 shared
Martha K. Terris
875 shared
Christopher J. Kane
University of California, San Diego
770 shared
Christopher L. Amling
Oregon Health & Science University
700 shared
Joseph C. Presti
Kaiser Permanente San Francisco Medical Center
550 shared
Matthew R. Cooperberg
307 shared
Lauren E. Howard
258 shared
David Elashoff
University of California, Los Angeles
127 shared

Education

MD, Medicine
Washington University in St. Louis

Similar researchers at University of California, Los Angeles

Resume-aware match score
Save to shortlist
AI-drafted outreach

See your match with William Aronson

PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.

Free to start
No credit card
30-second signup